Molecular Detection and Characterization

<<Return to Laboratory

Accredited by the Standards Council of Canada to Laboratory no. 594 - CAN-P-4E (ISO/IEC 17025)

Requisition Forms

Reference Details

Description:

Virus isolation and molecular characterization by real-time RT-PCR and VP1 sequencing.

Test Category:
Isolation and genotyping
Pathogen:
Poliovirus serotypes 1-3
Illnesses and Diseases:
  • Acute flaccid paralysis
  • Poliomyelitis (Polio) with clinical manifestations ranging from nonspecific mild illnesses including fever, sore throat, or gastrointestinal symptoms to aseptic meningitis
Specimen:
  • Stool – Required specimen type for poliovirus diagnostics as the likelihood of poliovirus isolation is the highest from stool.  To increase the probability of poliovirus isolation, obtain at least two stool specimens 24 hours apart from patients with suspected poliomyelitis.  These samples should be collected ideally within 14 days after onset.
  • Serum – Not recommended as this sample type is not likely to yield poliovirus in culture.
  • CSF – Not recommended as detection of poliovirus in this specimen type is uncommon.
  • Nasopharyngeal/Oropharyngeal Swab – Not recommended as respiratory specimens are not as likely as stool to yield poliovirus in culture.  However they may be useful in ruling out non-polio causes of acute flaccid paralysis (AFP).

Note:  If CSF, serum or respiratory swabs are sent for poliovirus testing, they will not undergo poliovirus isolation, they will be referred for Enterovirus and Human Parechovirus molecular detection and typing. 

Collection Method:
  • Stool – Collect within 14 days of illness onset and place in a sterile leak proof container, no special medium required.  Isolation rates are increased by obtaining 2 samples collected 24 hours apart.
Specimen Processing, Storage and Shipping:

Store samples, as soon as possible following collection, frozen at ≤-20°C until shipped for testing.  Ship frozen on dry ice.  Package Poliovirus samples in a separate shipping container from other samples being sent to the NML.

Transportation of Dangerous Goods:

Shipping of specimens shall be done by a TDG certified individual in accordance with TDG regulations. For additional information regarding classification of specimens for the purposes of shipping, consult either Part 2 Appendix 3 of the TDG Regulations or section 3.6.2 of the IATA Dangerous Goods Regulations as applicable.

For additional guidance on the transport of infectious substances in other languages, please click on the link below.

http://www.who.int/ihr/capacity-strengthening/infectious-substances/en/

Patient Criteria:

Cases of acute flaccid paralysis (AFP) in children less than 15 years of age and cases of suspected poliomyelitis in patients of any age.

Accompanying Documentation:

Completed Enteroviruses and Enteric viruses' requisition. If possible include relevant clinical findings, travel history, vaccination history, and any relevant lab results that have been completed at local or provincial laboratories.

Comments:

N/A

Methods and Interpretation of Results:

Laboratory Surveillance for wild polioviruses and genetically divergent vaccine-derived polioviruses (VDPVs) involves several WHO accredited methods:

  1.  Virus Isolation in Cell Culture: Following the WHO isolation algorithm, two cell lines, L20B and RD, are inoculated simultaneously with processed stool samples from suspect polio or AFP cases.  L20B positive isolates, which may be polio, are further typed by ITD and VDPV real time PCRs as described below.
  2. Typing of poliovirus isolates, and intratypic differentiation to distinguish Sabin-like from wild polioviruses: Polio group, serotype, and vaccine strain-specific molecular reagents that target defining PV properties within the capsid region (VP1) are used in a series of real time RT-PCR assays to determine serotype and to distinguish Sabin-like polioviruses from wild polioviruses (intratypic differentiation).  Sabin-like ITD result, the sample is tested by VDPV real time PCR; a non-Sabin-like ITD result, the sample is referred for VP1 RT-PCR and sequencing to confirm identity.
  3. Screening Sabin-like polioviruses for potential vaccine derived polioviruses (VDPVs): A real-time RT-PCR method targeting capsid region “hot spots” that typically revert in VDPVs is used to identify possible VDPVs once Sabin-like viruses have been identified using the intratypic differentiation methods described above.  With a Sabin-like VDPV result, the sample result is reported accordingly; with a non-Sabin like VDPV result, the sample is referred for VP1 RT-PCR and sequencing to confirm identity.
  4. Sequencing the VP1 region of non-Sabin-like and potential VDPV isolates:  A series of degenerate primers are used for VP1 sequencing of non-Sabin like poliovirus isolates identified by either ITD or VDPV real time PCRs described above.  Sequence data from the VP1 region is used to confirm the presence of a wild-type, a Sabin-like or a VDPV strains.  Further testing if required may be referred to the CDC in Atlanta, Georgia, which is the WHO GPLN Reference Laboratory.
Turnaround Time:

The total TAT is 28 calendar days.Each component of the test algorithm has its own allotted TAT and it is broken down as follows:

  • The TAT for PV Isolation is 14 calendar days from date the stool specimens are received into the lab. 
  • The TAT for PV ITD and PV VDPV real time RT-PCRs is 7 calendar days from the date the isolation is completed.
  • The TAT for PV VP1 sequencing is 7 calendar days from the date that the real time RT-PCR results are completed.
Contact:
Phone: (204) 789-2022
Fax: (204) 789-2082
Additional Contacts
Elsie Grudeski
Phone: 204-789-6067
Fax: 204-789-2082
References:
  1. World Health Organization. Polio Laboratory Manual. WHO/IVD/04.10,2004.
  2. S1. Supplement to the WHO Polio Laboratory manual-an Alternative Test Algorithm for Poliovirus Isolation and Detection.
  3. Kilpatick DR, Iber JC, Chen Q, Ching K, Yang S, De L, Mandelbaum MD, Emery B, Campagnoli R, Burns CC, Kew O. Poliovirus serotype-specific VP1 sequencing primers. J of Virol. Methods 174(2011) 128-130
Fact Sheets:
Related Information: